US Patent

US11027072 — Emergency devices

Formulation · Assigned to Adamis Pharmaceuticals Corp · Expires 2039-05-24 · 13y remaining

Vulnerability score 50/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects syringe devices containing a therapeutic dose of naloxone for treating opioid overdose.

USPTO Abstract

Described herein are syringe devices comprising a syringe including a therapeutic dose of at least one drug to be used in a drug or substance overdose. Also provided herein are compositions and methods of treating opioid overdose using high dose naloxone.

Drugs covered by this patent

naloxone-hydrochloride (Naloxone Hydrochloride) · Pfizer Inc.

Patent Metadata

Patent number: US11027072
Jurisdiction: US
Classification: Formulation
Expires: 2039-05-24
Drug substance claim: No
Drug product claim: Yes
Assignee: Adamis Pharmaceuticals Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.